logo-loader

Venn Life Sciences riding the Biotech wave

Published: 10:17 03 Jul 2015 EDT

AIM listed Venn Life Sciences (LON:VENN) CEO, Tony Richardson, tells Proactive Investors that he expects the solid first half momentum to continue, driven in part by strong demand from Biotechnology companies. He also sees increasing opportunities from medical device companies and mid sized pharmaceutical companies.Venn Life has a solid pipeline of potential opportunities which could be worth up to 18 million Euros. The company provides outsourced clinical contract research services and has recently been winning bigger contracts and taking on more staff. Richardson also sees acquisition opportunities in Central and Eastern Europe.

Poolbeg Pharma chair discusses shift to executive role; hVIVO share sale

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss his new hands-on role at the company. Stepping up as the executive chairman at Poolbeg Pharma, Friel expressed his intention to replicate the success he achieved with hVIVO, another...

on 02/15/2024